MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Context: Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone. Objective: The aim of this study was to evalua...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2011-09, Vol.96 (9), p.2889-2897 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2897 |
|---|---|
| container_issue | 9 |
| container_start_page | 2889 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 96 |
| creator | Bays, Harold E Schwartz, Sherwyn Littlejohn, Thomas Kerzner, Boris Krauss, Ronald M Karpf, David B Choi, Yun-Jung Wang, Xueyan Naim, Sue Roberts, Brian K |
| description | Context:
Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone.
Objective:
The aim of this study was to evaluate the effects of MBX-8025 (a novel PPAR-δ agonist) on lipid and other metabolic parameters associated with increased atherosclerotic risk, administered alone and in combination with atorvastatin.
Design and Setting:
This was a randomized, double-blind, placebo-controlled, parallel group proof-of-concept study conducted at 30 U.S. research sites.
Participants:
This study evaluated 181 overweight men and women with mixed dyslipidemia.
Intervention(s):
Subjects were administered once daily placebo, atorvastatin 20 mg, or MBX-8025 at 50 or 100 mg alone or combined with atorvastatin for 8 wk.
Main Outcome Measures:
The main efficacy measures included change from baseline in apolipoprotein B-100, lipid levels, high-sensitivity C-reactive protein, and additional metabolic parameters, as well as the effect on the metabolic syndrome and LDL particle size.
Results:
Compared to placebo, MBX-8025 alone and in combination with atorvastatin significantly (P < 0.05) reduced apolipoprotein B-100 20–38%, LDL 18–43%, triglycerides 26–30%, non-high-density lipoprotein cholesterol 18–41%, free fatty acids 16–28%, and high-sensitivity C-reactive protein 43–72%; it raised high-density lipoprotein cholesterol 1–12% and also reduced the number of patients with the metabolic syndrome and a preponderance of small LDL particles. MBX-8025 was safe and generally well-tolerated. MBX-8025 also reduced liver enzyme levels.
Conclusion:
MBX-8025, a novel PPAR-δ agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study. |
| doi_str_mv | 10.1210/jc.2011-1061 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888090101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1034814658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4804-cd2422f7567b4dafa6ae918ffb64bd6387385795b8eec79cdb1615bfe1fc81093</originalsourceid><addsrcrecordid>eNp90U9v0zAUAPAIgVgZ3DgjXxAcluGX2ImzWxnjj9TRCg1pt8hxnleXNC6207KvxJnPwWfCWQtcEJYsW9bvvWf7JclToKeQAX21UqcZBUiBFnAvmUDFeFpCVd5PJpRmkFZldn2UPPJ-RSkwxvOHyVEGJc-EoJPk--Xr61TQjJ-QKflot9iRBTr7zXi7RrJwtjManQzWkU-ocBM36c8fZHpje-PDGZmZjWmJ7FsyD0t05BKDbGKQIhdaowqemJ68ufXd6HAdz-dbdDs0N8tAFjIY7KO5cigDtmRnwvIu2bixQyDTWG8rfYiwf5w80LLz-OSwHief315cnb9PZ_N3H86ns1QxQVmq2oxlmS55UTaslVoWEisQWjcFa9oiF2UueFnxRiCqslJtAwXwRiNoJYBW-XHyYp934-zXAX2o18Yr7DrZox18LeLHVRQoRPnyvxJozgSwgotIT_ZUOeu9Q11vnFlLdxtRPfaxXql67GM99jHyZ4fMQ7PG9g_-3bgInh-A9Ep22sleGf_XMU6B3zm2dzvbBXT-Szfs0NVLlF1Y1jQOVpQiHSvHR1GaxpmzGJbvw7BvrXKmx41D7-uVHVwfP__ft_4FzcfISw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1034814658</pqid></control><display><type>article</type><title>MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Bays, Harold E ; Schwartz, Sherwyn ; Littlejohn, Thomas ; Kerzner, Boris ; Krauss, Ronald M ; Karpf, David B ; Choi, Yun-Jung ; Wang, Xueyan ; Naim, Sue ; Roberts, Brian K</creator><creatorcontrib>Bays, Harold E ; Schwartz, Sherwyn ; Littlejohn, Thomas ; Kerzner, Boris ; Krauss, Ronald M ; Karpf, David B ; Choi, Yun-Jung ; Wang, Xueyan ; Naim, Sue ; Roberts, Brian K</creatorcontrib><description>Context:
Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone.
Objective:
The aim of this study was to evaluate the effects of MBX-8025 (a novel PPAR-δ agonist) on lipid and other metabolic parameters associated with increased atherosclerotic risk, administered alone and in combination with atorvastatin.
Design and Setting:
This was a randomized, double-blind, placebo-controlled, parallel group proof-of-concept study conducted at 30 U.S. research sites.
Participants:
This study evaluated 181 overweight men and women with mixed dyslipidemia.
Intervention(s):
Subjects were administered once daily placebo, atorvastatin 20 mg, or MBX-8025 at 50 or 100 mg alone or combined with atorvastatin for 8 wk.
Main Outcome Measures:
The main efficacy measures included change from baseline in apolipoprotein B-100, lipid levels, high-sensitivity C-reactive protein, and additional metabolic parameters, as well as the effect on the metabolic syndrome and LDL particle size.
Results:
Compared to placebo, MBX-8025 alone and in combination with atorvastatin significantly (P < 0.05) reduced apolipoprotein B-100 20–38%, LDL 18–43%, triglycerides 26–30%, non-high-density lipoprotein cholesterol 18–41%, free fatty acids 16–28%, and high-sensitivity C-reactive protein 43–72%; it raised high-density lipoprotein cholesterol 1–12% and also reduced the number of patients with the metabolic syndrome and a preponderance of small LDL particles. MBX-8025 was safe and generally well-tolerated. MBX-8025 also reduced liver enzyme levels.
Conclusion:
MBX-8025, a novel PPAR-δ agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2011-1061</identifier><identifier>PMID: 21752880</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Aged ; Atorvastatin Calcium ; Biological and medical sciences ; C-Reactive Protein - metabolism ; Double-Blind Method ; Drug Therapy, Combination ; Dyslipidemias - complications ; Dyslipidemias - drug therapy ; Dyslipidemias - metabolism ; Endocrinopathies ; Enzymes ; Feeding. Feeding behavior ; Female ; Fundamental and applied biological sciences. Psychology ; Heptanoic Acids - pharmacology ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Lipids ; Lipids - blood ; Liver ; Liver - drug effects ; Liver - metabolism ; Male ; Medical sciences ; Middle Aged ; Obesity ; Overweight - complications ; Overweight - drug therapy ; Overweight - metabolism ; Patients ; PPAR delta - agonists ; Proteins ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Research (statistical design) ; Self efficacy ; Treatment Outcome ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vertebrates: endocrinology ; Women</subject><ispartof>The journal of clinical endocrinology and metabolism, 2011-09, Vol.96 (9), p.2889-2897</ispartof><rights>Copyright © 2011 by The Endocrine Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4804-cd2422f7567b4dafa6ae918ffb64bd6387385795b8eec79cdb1615bfe1fc81093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24501580$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21752880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bays, Harold E</creatorcontrib><creatorcontrib>Schwartz, Sherwyn</creatorcontrib><creatorcontrib>Littlejohn, Thomas</creatorcontrib><creatorcontrib>Kerzner, Boris</creatorcontrib><creatorcontrib>Krauss, Ronald M</creatorcontrib><creatorcontrib>Karpf, David B</creatorcontrib><creatorcontrib>Choi, Yun-Jung</creatorcontrib><creatorcontrib>Wang, Xueyan</creatorcontrib><creatorcontrib>Naim, Sue</creatorcontrib><creatorcontrib>Roberts, Brian K</creatorcontrib><title>MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context:
Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone.
Objective:
The aim of this study was to evaluate the effects of MBX-8025 (a novel PPAR-δ agonist) on lipid and other metabolic parameters associated with increased atherosclerotic risk, administered alone and in combination with atorvastatin.
Design and Setting:
This was a randomized, double-blind, placebo-controlled, parallel group proof-of-concept study conducted at 30 U.S. research sites.
Participants:
This study evaluated 181 overweight men and women with mixed dyslipidemia.
Intervention(s):
Subjects were administered once daily placebo, atorvastatin 20 mg, or MBX-8025 at 50 or 100 mg alone or combined with atorvastatin for 8 wk.
Main Outcome Measures:
The main efficacy measures included change from baseline in apolipoprotein B-100, lipid levels, high-sensitivity C-reactive protein, and additional metabolic parameters, as well as the effect on the metabolic syndrome and LDL particle size.
Results:
Compared to placebo, MBX-8025 alone and in combination with atorvastatin significantly (P < 0.05) reduced apolipoprotein B-100 20–38%, LDL 18–43%, triglycerides 26–30%, non-high-density lipoprotein cholesterol 18–41%, free fatty acids 16–28%, and high-sensitivity C-reactive protein 43–72%; it raised high-density lipoprotein cholesterol 1–12% and also reduced the number of patients with the metabolic syndrome and a preponderance of small LDL particles. MBX-8025 was safe and generally well-tolerated. MBX-8025 also reduced liver enzyme levels.
Conclusion:
MBX-8025, a novel PPAR-δ agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study.</description><subject>Adult</subject><subject>Aged</subject><subject>Atorvastatin Calcium</subject><subject>Biological and medical sciences</subject><subject>C-Reactive Protein - metabolism</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Dyslipidemias - complications</subject><subject>Dyslipidemias - drug therapy</subject><subject>Dyslipidemias - metabolism</subject><subject>Endocrinopathies</subject><subject>Enzymes</subject><subject>Feeding. Feeding behavior</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heptanoic Acids - pharmacology</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Lipids</subject><subject>Lipids - blood</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Overweight - complications</subject><subject>Overweight - drug therapy</subject><subject>Overweight - metabolism</subject><subject>Patients</subject><subject>PPAR delta - agonists</subject><subject>Proteins</subject><subject>Pyrroles - pharmacology</subject><subject>Pyrroles - therapeutic use</subject><subject>Research (statistical design)</subject><subject>Self efficacy</subject><subject>Treatment Outcome</subject><subject>Vertebrates: anatomy and physiology, studies on body, several organs or systems</subject><subject>Vertebrates: endocrinology</subject><subject>Women</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90U9v0zAUAPAIgVgZ3DgjXxAcluGX2ImzWxnjj9TRCg1pt8hxnleXNC6207KvxJnPwWfCWQtcEJYsW9bvvWf7JclToKeQAX21UqcZBUiBFnAvmUDFeFpCVd5PJpRmkFZldn2UPPJ-RSkwxvOHyVEGJc-EoJPk--Xr61TQjJ-QKflot9iRBTr7zXi7RrJwtjManQzWkU-ocBM36c8fZHpje-PDGZmZjWmJ7FsyD0t05BKDbGKQIhdaowqemJ68ufXd6HAdz-dbdDs0N8tAFjIY7KO5cigDtmRnwvIu2bixQyDTWG8rfYiwf5w80LLz-OSwHief315cnb9PZ_N3H86ns1QxQVmq2oxlmS55UTaslVoWEisQWjcFa9oiF2UueFnxRiCqslJtAwXwRiNoJYBW-XHyYp934-zXAX2o18Yr7DrZox18LeLHVRQoRPnyvxJozgSwgotIT_ZUOeu9Q11vnFlLdxtRPfaxXql67GM99jHyZ4fMQ7PG9g_-3bgInh-A9Ep22sleGf_XMU6B3zm2dzvbBXT-Szfs0NVLlF1Y1jQOVpQiHSvHR1GaxpmzGJbvw7BvrXKmx41D7-uVHVwfP__ft_4FzcfISw</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Bays, Harold E</creator><creator>Schwartz, Sherwyn</creator><creator>Littlejohn, Thomas</creator><creator>Kerzner, Boris</creator><creator>Krauss, Ronald M</creator><creator>Karpf, David B</creator><creator>Choi, Yun-Jung</creator><creator>Wang, Xueyan</creator><creator>Naim, Sue</creator><creator>Roberts, Brian K</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin</title><author>Bays, Harold E ; Schwartz, Sherwyn ; Littlejohn, Thomas ; Kerzner, Boris ; Krauss, Ronald M ; Karpf, David B ; Choi, Yun-Jung ; Wang, Xueyan ; Naim, Sue ; Roberts, Brian K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4804-cd2422f7567b4dafa6ae918ffb64bd6387385795b8eec79cdb1615bfe1fc81093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atorvastatin Calcium</topic><topic>Biological and medical sciences</topic><topic>C-Reactive Protein - metabolism</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Dyslipidemias - complications</topic><topic>Dyslipidemias - drug therapy</topic><topic>Dyslipidemias - metabolism</topic><topic>Endocrinopathies</topic><topic>Enzymes</topic><topic>Feeding. Feeding behavior</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heptanoic Acids - pharmacology</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Lipids</topic><topic>Lipids - blood</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Overweight - complications</topic><topic>Overweight - drug therapy</topic><topic>Overweight - metabolism</topic><topic>Patients</topic><topic>PPAR delta - agonists</topic><topic>Proteins</topic><topic>Pyrroles - pharmacology</topic><topic>Pyrroles - therapeutic use</topic><topic>Research (statistical design)</topic><topic>Self efficacy</topic><topic>Treatment Outcome</topic><topic>Vertebrates: anatomy and physiology, studies on body, several organs or systems</topic><topic>Vertebrates: endocrinology</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bays, Harold E</creatorcontrib><creatorcontrib>Schwartz, Sherwyn</creatorcontrib><creatorcontrib>Littlejohn, Thomas</creatorcontrib><creatorcontrib>Kerzner, Boris</creatorcontrib><creatorcontrib>Krauss, Ronald M</creatorcontrib><creatorcontrib>Karpf, David B</creatorcontrib><creatorcontrib>Choi, Yun-Jung</creatorcontrib><creatorcontrib>Wang, Xueyan</creatorcontrib><creatorcontrib>Naim, Sue</creatorcontrib><creatorcontrib>Roberts, Brian K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bays, Harold E</au><au>Schwartz, Sherwyn</au><au>Littlejohn, Thomas</au><au>Kerzner, Boris</au><au>Krauss, Ronald M</au><au>Karpf, David B</au><au>Choi, Yun-Jung</au><au>Wang, Xueyan</au><au>Naim, Sue</au><au>Roberts, Brian K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2011-09</date><risdate>2011</risdate><volume>96</volume><issue>9</issue><spage>2889</spage><epage>2897</epage><pages>2889-2897</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Context:
Preclinical and clinical studies suggest that peroxisome proliferator-activated receptor (PPAR)-δ agonists favorably affect multiple metabolic parameters that are otherwise proatherogenic, many that are not optimally managed with statins alone.
Objective:
The aim of this study was to evaluate the effects of MBX-8025 (a novel PPAR-δ agonist) on lipid and other metabolic parameters associated with increased atherosclerotic risk, administered alone and in combination with atorvastatin.
Design and Setting:
This was a randomized, double-blind, placebo-controlled, parallel group proof-of-concept study conducted at 30 U.S. research sites.
Participants:
This study evaluated 181 overweight men and women with mixed dyslipidemia.
Intervention(s):
Subjects were administered once daily placebo, atorvastatin 20 mg, or MBX-8025 at 50 or 100 mg alone or combined with atorvastatin for 8 wk.
Main Outcome Measures:
The main efficacy measures included change from baseline in apolipoprotein B-100, lipid levels, high-sensitivity C-reactive protein, and additional metabolic parameters, as well as the effect on the metabolic syndrome and LDL particle size.
Results:
Compared to placebo, MBX-8025 alone and in combination with atorvastatin significantly (P < 0.05) reduced apolipoprotein B-100 20–38%, LDL 18–43%, triglycerides 26–30%, non-high-density lipoprotein cholesterol 18–41%, free fatty acids 16–28%, and high-sensitivity C-reactive protein 43–72%; it raised high-density lipoprotein cholesterol 1–12% and also reduced the number of patients with the metabolic syndrome and a preponderance of small LDL particles. MBX-8025 was safe and generally well-tolerated. MBX-8025 also reduced liver enzyme levels.
Conclusion:
MBX-8025, a novel PPAR-δ agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>21752880</pmid><doi>10.1210/jc.2011-1061</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2011-09, Vol.96 (9), p.2889-2897 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_888090101 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adult Aged Atorvastatin Calcium Biological and medical sciences C-Reactive Protein - metabolism Double-Blind Method Drug Therapy, Combination Dyslipidemias - complications Dyslipidemias - drug therapy Dyslipidemias - metabolism Endocrinopathies Enzymes Feeding. Feeding behavior Female Fundamental and applied biological sciences. Psychology Heptanoic Acids - pharmacology Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Lipids Lipids - blood Liver Liver - drug effects Liver - metabolism Male Medical sciences Middle Aged Obesity Overweight - complications Overweight - drug therapy Overweight - metabolism Patients PPAR delta - agonists Proteins Pyrroles - pharmacology Pyrroles - therapeutic use Research (statistical design) Self efficacy Treatment Outcome Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: endocrinology Women |
| title | MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T23%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MBX-8025,%20A%20Novel%20Peroxisome%20Proliferator%20Receptor-%CE%B4%20Agonist:%20Lipid%20and%20Other%20Metabolic%20Effects%20in%20Dyslipidemic%20Overweight%20Patients%20Treated%20with%20and%20without%20Atorvastatin&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Bays,%20Harold%20E&rft.date=2011-09&rft.volume=96&rft.issue=9&rft.spage=2889&rft.epage=2897&rft.pages=2889-2897&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2011-1061&rft_dat=%3Cproquest_cross%3E1034814658%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1034814658&rft_id=info:pmid/21752880&rfr_iscdi=true |